Abstract 535P
Background
Copy number alterations (CNAs) are common consequences of genome instability in lung cancer. Focal amplifications in NKX2-1 copy number (CN) have been frequently observed in non-small cell lung cancer (NSCLC). However, beyond CN gain, little is known about the complete landscape of NKX2-1 CNAs, their clinical significance, and their therapeutic implications in NSCLC.
Methods
Correlations of NKX2-1 expression with EGFR driver mutations and PD-L1 co-expression were studied using immunohistochemistry and PCR from tumors of recruited Filipino patients (n=45). Clinical features of NSCLC with NKX2-1 CNAs were resolved at the tumor and clonal levels using the molecular profiles of LUAD and LUSC participants from TCGA (n=1,130), and deconvoluted single-cell RNA-seq data from Bivona project (n=1,654), respectively.
Results
NKX2-1 expression and CN variations correlated significantly (r= 0.264; p<0.001). However, NKX2-1 CNAs exert a stronger influence on the combined EGFR and PD-L1 status of NSCLC tumors (p<0.05) than expression (p>0.05). NKX2-1 CN gain was prognostic of favorable survival (p=0.018), whereas, NKX2-1 CN loss prognosed worse survival (p=0.041). Mutational architecture in Y-chromosome differentiates the two prognostic groups. There were 19,941 synonymous mutations and 1,408 genome-wide CN perturbations associated with NKX2-1 CNAs. Tumors with NKX2-1 CN gain had higher B cell (p<0.001) and total T cell estimates (p=0.003). NKX2-1 CN loss was associated with colder tumors due to higher M2 macrophage infiltrates (p=0.011) and higher expression of immune checkpoint proteins, CD274 (p=0.025), VTCN1 (p<0.001), and LGALS9 (p=0.002). Lymphocyte marker signature in CN gain was prognostic of longer disease-free survival (p=0.005).
Conclusions
NKX2-1 CNAs are associated with tumors that exhibit clinically diverse characteristics, and with unique oncogenic, immunologic, and prognostic signatures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Science and Technology - Philippine Council for Health Research and Development.
Funding
Department of Science and Technology - Philippine Council on Health Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract